The DOI matches its Crossref record; 55 of the 57 references it cites were found in a registry or an index.
The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review
Abstract
OBJECTIVES: Patients with RA have an increased prevalence of cardiovascular disease (CVD). This is due to traditional risk factors and the effects of chronic inflammation. MTX is the first-choice DMARD in RA. We performed a systematic literature review to determine whether MTX affects the risk of CVD in patients with RA. METHODS: We searched Medline, Embase, Cochrane database, database of abstracts of reviews of effects, health technology assessment and Science Citation Index from 1980 to 2008. Conference proceedings (British Society of Rheumatology, ACR and EULAR) were searched from 2005 to 2008. Papers were included if they assessed the relationship between MTX use and CVD in patients with RA. Two reviewers independently assessed each title and abstract for relevance and quality. RESULTS: A total of 2420 abstracts were identified, of which 18 fulfilled the inclusion criteria. Two studies assessed the relationship between MTX use and CVD mortality, one demonstrated a significant reduction in CVD mortality and the second a trend towards reduction. Five studies considered all-cause CVD morbidity. Four demonstrated a significant reduction in CVD morbidity and the fifth a trend towards reduction. MTX use in the year prior to the development of RA decreased the risk of CVD for 3-4 years. Four studies considered myocardial infarction, one demonstrated a decreased risk and three a trend towards decreased risk with MTX use. CONCLUSION: The current evidence suggests that MTX use is associated with a reduced risk of CVD events in patients with RA. This suggests that reducing the inflammation in RA using MTX not only improves disease-specific outcomes but may also reduce collateral damage such as atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Non-randomized observational studies report reductions in rates of vascular events and cardiovascular death among both rheumatoid arthritis and psoriasis patients being treated with weekly methotrexate in doses ranging from 10 to 20 mg.187,188”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [187]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Sanderson, S., Tatt, I. D., & Higgins, J. P. (2007) · International Journal of Epidemiology · doi:10.1093/ije/dym018 · Cited by 1,531
Being big or growing fast: systematic review of size and growth in infancy and later obesity
Baird, J., Fisher, D., Lucas, P., Kleijnen, J., Roberts, H., & Law, C. (2005) · BMJ · doi:10.1136/bmj.38586.411273.e0 · Cited by 1,185
Self-citationMethotrexate and mortality in patients with rheumatoid arthritis: a prospective study
Choi, H. K., Hernán, M. Á., Seeger, J. D., Robins, J. M., & Wolfe, F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08213-2 · Cited by 1,133
Cardiovascular Risk and Inhibition of Cyclooxygenase
McGettigan, P., & Henry, D. A. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60011 · Cited by 1,106
Cardiovascular death in rheumatoid arthritis: A population‐based study
Kremers, H. M., Nicola, P., Crowson, C. S., Ballman, K. V., & Gabriel, S. E. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20878 · Cited by 941
Explaining How “High-Grade” Systemic Inflammation Accelerates Vascular Risk in Rheumatoid Arthritis
Sattar, N. A., McCarey, D. W., Capell, H. A., & McInnes, I. B. (2003) · Circulation · doi:10.1161/01.cir.0000099844.31524.05 · Cited by 932
Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis
Weinblatt, M. E., Coblyn, J. S., Fox, D. A., Fraser, P. A., Holdsworth, D. E., Glass, D. N., & Trentham, D. E. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503283121303 · Cited by 872
Ridker, P. M., Wilson, P. W. F., & Grundy, S. M. (2004) · Circulation · doi:10.1161/01.cir.0000132467.45278.59 · Cited by 645
Research works printed but not linked: 11
- Symmons, 1998, The Journal of Rheumatology, 25, 1072
- 1985, CLINICAL AND IMMUNOLOGIC EFFECTS IN A RANDOMIZED DOUBLEBLIND STUDY ANN INTERN MED, 103, 489
- 1985, A CONTROLLED CLINICAL TRIAL ARTHRITIS RHEUM, 28, 721
- Thompson, 1984, The Journal of Rheumatology, 11, 760
- 2008, Rheumatology, 47, ii49
- 2006, Annals of the Rheumatic Diseases, 65, 307
- 2008, Arthritis and rheumatism, 56, 688
- 2007, Arthritis and rheumatism, 56, S293
- GOODSON, 2008, The Journal of Rheumatology, 35, 945
- Seriolo, 2008, Clinical and experimental rheumatology, 26, 159
- Morgan, 1998, The Journal of Rheumatology, 25, 441
Cited by
Sorted by citations
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
European guidelines on cardiovascular disease prevention in clinical practice: executive summary
Graham, I., Atar, D., Borch‐Johnsen, K., Boysen, G., Burell, G. K., Cífková, R., Dallongeville, J., Backer, G. D., Ebrahim, S. B. J., Gjelsvik, B., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,862
Smolen, J. S., Landewé, R., Breedveld, F. C., Buch, M. H., Burmester, G. R., Dougados, M., Emery, P., Gaujoux-Viala, C., Gossec, L., Nam, J. L., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204573 · Cited by 1,764
Smolen, J. S., Breedveld, F. C., Burmester, G. R., Bykerk, V. P., Dougados, M., Emery, P., Kvien, T. K., Navarro-Compán, M. V., Oliver, S. M., Schoels, M., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207524 · Cited by 1,481
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Authors/Task Force Members, Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M. T., Corrà, U., Cosyns, B., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316653709 · Cited by 1,431
Metadata
- Authors
- Westlake, S. L., Colebatch, A. N., Baird, J., Kiely, P., Quinn, M., Choy, E., Ostor, A. J. K., & Edwards, C. J.
- Affiliations
- King's College London (GB)
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-11-27
- Volume
- 49
- Issue
- 2
- Pages
- 295-307
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2100260684
- Cited by
- 357
- References
- 57
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 7 · 2023: 10 · 2022: 15 · 2021: 18 · 2020: 15 · 2019: 26 · 2018: 20 · 2017: 25 · 2016: 32 · 2015: 38 · 2014: 25 · 2013: 33 · 2012: 42
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Lara D. Veeken (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Nephrology › Gout, Hyperuricemia, Uric Acid
- Keywords
- methotrexate, rheumatoid arthritis, cardiovascular disease, cardiovascular mortality, cardiovascular morbidity, myocardial infarction, atherosclerosis, disease-modifying antirheumatic drugs, chronic inflammation
- MeSH terms
- Arthritis, Rheumatoid, Cardiovascular Diseases, Humans, Immunosuppressive Agents, Insulin Resistance, Lipids, Methotrexate, Antirheumatic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
